Kiadis announces publication in Blood highlighting proof-of-concept to enhance potency of anti-CD38 antibodies with Kiadis’ K-NK004, recently licensed by Sanofi

NEXT STORY
Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine
PREV STORY
The Global Microbial Testing Market is expected to grow by $ 2.83 bn during 2020-2024 progressing at a CAGR of 7% during the forecast period
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Pfizer and BioNTech Reach an Agreement to Supply the EU with 200 Million Doses of Their BNT162b2 mRNA-based Vaccine Candidate against COVID-19

author_avatar
NASDAQ Market News

Inovio will Independently Develop Hepatitis B Immunotherapy

PLYMOUTH MEETING, Pa., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today ...

author_avatar
NASDAQ Market News

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

author_avatar
NASDAQ Market News